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4% increased in size (Table 2). Of 327 patients who were 
symptomatic prior to treatment, 17% had a complete reso-
lution of symptoms, 41% had improvement, 36% had sta-
bility, and 6% had deterioration after radiotherapy. Crude 
LC was 90%-100% as reported in 10  studies. Actuarial 
LC rates, reported in 2 studies, were 89% and 92 ± 3% at 
3 years. Median 5-year PFS was 88% as reported in 4 stud-
ies. Recognizing the popularity of hSRT dose schedules 
of ≤ 5 fractions, treatment response and crude LC rates 
were also summarized for studies with these prescriptions 
(Table 2).
Overall, the median late toxicity rate was 8% with a 
range of 0% to 21% (Table 3). The median late toxicity rates 
for tumors involving the skull base and optic structures 
were 5% and 9%, respectively. The majority of the reported 
toxicities were Grades 1–2, and the most common late tox-
icities were decreased visual acuity in 8 patients and new 
cranial neuropathy in 11 patients. Grade 3 or higher tox-
icity was observed in 1 study, which reported 3 patients 
who developed Grade 3 or 4 deficits. These were seizure, 
gait disturbance, and bilateral vision loss. As above, for 
patients receiving hSRT in 5 fractions or less, the late tox-
icities were also summarized (Table 3).
Discussion
To our knowledge, this is the first systematic review exam-
ining the use of hSRT in ICMs. A  previous systematic 
review by Chung et al4 compared the outcomes achieved 
with cRT vs SRS; however, apart from 2 studies that 
included patients receiving staged radiosurgery, the re-
view predominantly assessed single-fraction SRS. Our 
study demonstrates excellent local control rates with hSRT, 
ranging from 90% to 100%, and 5-year PFS of 81%-98%. In 
comparison to single-fraction SRS and cRT, hSRT is well 
tolerated, with Grade 3 or greater late toxicity rates rang-
ing from 0% to 9.7%.
Studies with a larger median tumor volume (>20 cc) 
appeared to have lower LC rates. Maranzano and col-
leagues20 had the lowest reported LC at 5 years with a me-
dian tumor volume of 23 cc, while a study by Demiral et al,15 
which had the largest median tumor size of 26 cc, showed 
an LC rate of only 89%, as well as the highest late toxicity 
rate of 21.1%. This trend is in keeping with SRS studies 
that have shown worse outcomes with larger ICMs.21,22 All 
included studies primarily examined WHO Grade I  ICMs 
based on histology or imaging alone. For tumors in which 
histology was available, only 2  studies had more than 2 
patients with Grade II or greater ICMs.10,20 One of these did 
find lower LC and disease-specific survival in their grade II 
cohort, while the other study, which included a mixture both 
of Grade II and III ICMs, showed significantly worse 3-year 
and 5-year PFS.
The outcomes for ICMs treated with hSRT compare 
favorably to the published literature for single-fraction 
SRS and cRT. In the review by Chung and colleagues,4 
28  articles were reviewed, including 3683 patients 
treated with SRS or cRT. The mean 5-year PFS was 93.2% 
for SRS and 91.8% for cRT. Both modalities had a similar 
mean complication rate of approximately 10%. These 
data are very similar to the outcomes we observed for 
patients treated with hSRT. Further to this point, one of 
our included series by Han et al19 reported no significant 
differences in clinical response, late toxicities, radio-
graphic tumor control, or PFS among hSRT, SRS, and 
cRT. Albert and colleagues23 demonstrated a trend to-
ward improved 3-year overall survival in postoperative 
patients receiving SRS or hSRT compared to cRT, but this 
difference was not statistically significant. The Response 
Assessment in Neuro-Oncology working group also con-
ducted a review of 70 studies comparing radiotherapy 
modalities in low-grade ICMs.3 For SRS and cRT, median 
clinical responses to treatment were 29% and 43.2%, 
respectively, and median radiographic responses were 
49% and 23%, respectively. The higher radiographic re-
gression following SRS has been observed in other stud-
ies as well and is postulated to be an effect of high-dose 
radiation overcoming radioresistance in targeted tissue.4 
Median radiologic response across the included hSRT 
studies was only 14% but ranged widely from 6% to 41%. 
Generally, patients are counseled to expect tumor sta-
bility rather than shrinkage as the most common out-
come following radiotherapy, which is supported by our 
finding that radiographic stability ranged from 52% to 
98% across included studies. There was excellent clin-
ical response in the studies we examined with a median 
of 59%.
While SRS provides favorable benefits to some 
patients, there are limitations to its widespread applica-
tion. Larger tumors or those in non–skull-base locations 
typically have a higher risk of adverse radiation reactions, 
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compromising the utility of SRS as alternative therapy in 
patients who are not operable because of tumor size or lo-
cation.24 In one series, 38.2% of patients receiving SRS for 
parafalcine or parasagittal ICM developed new or wors-
ened perilesional swelling, with tumor size and venous 
sinus invasion being predictive factors for post-SRS 
edema.25,26 In addition, Patil et  al27 found that patients 
with parasagittal meningiomas were more than 4 times 
as likely to develop symptomatic edema after SRS than 
nonparasagittal ICMs. Finally, Pollock and colleagues26,28 
reported higher complication rates when treating larger 
ICMs (>10 cc) with SRS.
As an alternative to single-fraction SRS, hSRT potentially 
provides a broader scope of application. Rates of peritumoral 
edema appear to be low, as Morimoto et al17 found 19% of 
patients receiving hSRT had treatment-associated edema.
Unger and colleagues29 reported lower rates of symptomatic 
edema with hSRT compared to SRS with 2-year rates of 3.2% 
and 12.5%, respectively. Additionally, hypofractionation has 
fewer restrictions with regards to tumor location. A study by 
Columbo et al30 found that patients with ICMs close to critical 
structures had low rates of toxicities when treated using hSRT 
and included 63 patients who could not have been treated by 
SRS otherwise. Further support for the relative safety of hSRT 
was demonstrated in a report31 that described hSRT symp-
tomatic edema rates of 6.3%, compared to 43% with SRS 
when treating ICMs in convexity or parasagittal locations.
From a radiobiological perspective, fractionation allows 
clinicians to take advantage of differences in alpha-beta 
ratios between tumor and normal tissue to potentially im-
prove the therapeutic ratio. As described in an example 
outlined by Kirkpatrick and colleagues,24 compared to sin-
gle-fraction SRS, a hypofractionated regimen can maintain 
the biological effective dose (BED) to tumor while reduc-
ing normal tissue toxicity. In addition, the higher dose per 
fraction may theoretically improve LC compared to cRT, 
although no prospective study has shown superiority of 
one modality over another.23 While most of the studies 
included in the present report delivered ≥5 Gy per fraction, 
5 studies included patients receiving 14 to 15 fractions 
with less than or equal to 3 Gy per fraction.7,10,11,16,20 This 
moderately hypofractionated cohort may differ from the 
more common regimen of 5 fractions or less. In particular, 
one of these studies reported the lowest 5-year LC rate of 
84%, one had a relatively low median LC of 24 months, 
and another had a 5-year PFS of only 80.9%.10,16,20 While 
Table 2 Summary of Treatment Outcomes for all Included Studies and for Studies that Delivered hSRT in 2-5 Fractions
Outcome All Included Studies (n = 14; Pts = 630) Studies with hSRT in 2-5 Fractions (n = 9; 
Pts = 331)
% n Pts % n Pts
Clinical Response
Median 45 43




















Range 81-98 4 323 87-93 2 174
Mean 89 90
Abbreviations: hSRT, hypofractionated stereotactic radiotherapy; PFS, progression-free survival; Pts, patients.
















these findings are in support of the theory that higher 
doses per fraction offer superior control, no conclusions 
can be drawn based on the limited evidence at the present 
time. Conversely, extreme hypofractionation can be po-
tentially harmful. The only study that reported Grade III-IV 
late toxicity had a higher average dose per fraction. The 
patient who experienced Grade  IV toxicity received the 
largest dose of 36 Gy in 3 fractions.17
BED allows dose fractionation schedules to be com-
pared, and these values can be estimated for benign 
meningiomas based on a previously reported32 alpha-
beta ratio of 3. For all included studies, the BED ranged 
from 37.33 to 180 Gy3, with outcomes and toxicities sum-
marized in Tables 2 and 3. The most common prescription 
was 25 Gy in 5 fractions, which was associated with a BED 
of 66.67 Gy3. Three studies that exclusively used this frac-
tionation achieved local control rates of 89%, 100%, and 
100%.13,15,19 Two studies that delivered lower BED dose 
fractionations (<40 Gy3) had slightly inferior local control 
rates of 90% and 95%, but the number of patients receiv-
ing these schedules was relatively low.8,14 Studies that 
delivered moderately hypofractionated dose regimens in 
14-15 fractions had a BED of 57.2-90 Gy3, which is compar-
able to the 2-5 fraction regimens. A significant caveat that 
limits our ability to truly compare these dose schedules 
based on BED alone is the variability in which isodose 
level (IDL) was prescribed to, with most studies reporting 
this information only as a median or range. A course of 
25 Gy in 5 fractions prescribed to the 80% IDL would result 
in a higher dose within the tumor as the same course pre-
scribed to the 100% IDL. Taken together the heterogeneity 
in dose fractionations across studies and uncertainties in 
which IDL each dose regimen was prescribed to prohib-
its any strong conclusions or recommendations based on 
these data.
There are several limitations to this review worth not-
ing. First, the study is retrospective in nature and only 
descriptive analyses were completed given the substan-
tial heterogeneity between studies, most notably in dose 
fractionation delivered and outcomes reported. Second, 
there was a relatively short follow-up duration across 
a number of studies. Longer follow-up will be essential 
to confirm an acceptable toxicity profile but also to as-
certain the true LC rates with hSRT given the indolent 
biology of this mostly Grade I meningioma population. 
Third, studies with a mixed cohort of hSRT with either 
SRS or cRT were excluded in an effort to obtain a data-
set of only meningiomas treated with hSRT. The reports 
omitted through this approach may have had an impact 
on our results. Finally, there were several studies that did 
not meet the minimum median follow-up time of 2 years 
that were also excluded.
Conclusion
Larger, prospective studies with extended follow-up are 
required to fully characterize the tolerability and long-term con-
trol of hSRT for ICMs and assess how it truly compares to SRS 
and cRT. Until then, this systematic review supports the appli-
cation of hSRT as an effective and safe therapeutic option for 
ICMs. It remains a reasonable alternative to SRS for tumors 
inappropriate for single-fraction radiotherapy, provides the 
Table 3 Summary of Toxicities for All Included Studies and for Studies that Delivered hSRT in 2-5 Fractions
Late Toxicity All Included Studies (n = 14; Pts = 630) Studies With hSRT in 2-5 Fractions  
(n = 9; Pts = 331)
% n Pts % n Pts
Overall Late Toxicity
Median 8 8
Range 0-21 12 512 0-21 8 305
Mean 8 8
Overall > Grade 3 Toxicitys
Median 0 0








Range 8-10 2  46 8-10 2  46
Mean 9 9
Abbreviations: hSRT, hypofractionated stereotactic radiotherapy; Pts, patients.
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radiobiological advantages of fractionation, and allows for a 
shorter and more convenient treatment course for patients.
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Supplementary material is available at Neuro-Oncology 
Practice online.
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